Tollefson A E, Toth K, Doronin K, Kuppuswamy M, Doronina O A, Lichtenstein D L, Hermiston T W, Smith C A, Wold W S
Department of Molecular Microbiology and Immunology, St. Louis University Health Sciences Center, St. Louis, Missouri 63104, USA.
J Virol. 2001 Oct;75(19):8875-87. doi: 10.1128/JVI.75.19.8875-8887.2001.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis through two receptors, TRAIL-R1 (also known as death receptor 4) and TRAIL-R2 (also known as death receptor 5), that are members of the TNF receptor superfamily of death domain-containing receptors. We show that human adenovirus type 5 encodes three proteins, named RID (previously named E3-10.4K/14.5K), E3-14.7K, and E1B-19K, that independently inhibit TRAIL-induced apoptosis of infected human cells. This conclusion was derived from studies using wild-type adenovirus, adenovirus replication-competent mutants that lack one or more of the RID, E3-14.7K, and E1B-19K genes, and adenovirus E1-minus replication-defective vectors that express all E3 genes, RID plus E3-14.7K only, RID only, or E3-14.7K only. RID inhibits TRAIL-induced apoptosis when cells are sensitized to TRAIL either by adenovirus infection or treatment with cycloheximide. RID induces the internalization of TRAIL-R1 from the cell surface, as shown by flow cytometry and indirect immunofluorescence for TRAIL-R1. TRAIL-R1 was internalized in distinct vesicles which are very likely to be endosomes and lysosomes. TRAIL-R1 is degraded, as indicated by the disappearance of the TRAIL-R1 immunofluorescence signal. Degradation was inhibited by bafilomycin A1, a drug that prevents acidification of vesicles and the sorting of receptors from late endosomes to lysosomes, implying that degradation occurs in lysosomes. RID was also shown previously to internalize and degrade another death domain receptor, Fas, and to prevent apoptosis through Fas and the TNF receptor. RID was shown previously to force the internalization and degradation of the epidermal growth factor receptor. E1B-19K was shown previously to block apoptosis through Fas, and both E1B-19K and E3-14.7K were found to prevent apoptosis through the TNF receptor. These findings suggest that the receptors for TRAIL, Fas ligand, and TNF play a role in limiting virus infections. The ability of adenovirus to inhibit killing through these receptors may prolong acute and persistent infections.
肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)通过两种受体诱导细胞凋亡,即TRAIL-R1(也称为死亡受体4)和TRAIL-R2(也称为死亡受体5),它们是含死亡结构域的TNF受体超家族成员。我们发现,人5型腺病毒编码三种蛋白,分别命名为RID(以前称为E3-10.4K/14.5K)、E3-14.7K和E1B-19K,它们可独立抑制TRAIL诱导的被感染人细胞凋亡。该结论来自于对野生型腺病毒、缺乏RID、E3-14.7K和E1B-19K基因中的一个或多个的腺病毒复制能力突变体,以及表达所有E3基因、仅表达RID加E3-14.7K、仅表达RID或仅表达E3-14.7K的腺病毒E1缺失复制缺陷载体的研究。当细胞通过腺病毒感染或用环己酰亚胺处理而对TRAIL敏感时,RID可抑制TRAIL诱导的细胞凋亡。如通过流式细胞术和TRAIL-R1的间接免疫荧光所示,RID可诱导TRAIL-R1从细胞表面内化。TRAIL-R1被内化到不同的囊泡中,这些囊泡很可能是内体和溶酶体。如TRAIL-R1免疫荧光信号的消失所示,TRAIL-R1被降解。巴弗洛霉素A1可抑制降解,该药物可防止囊泡酸化以及受体从晚期内体分选到溶酶体,这意味着降解发生在溶酶体中。之前还表明,RID可内化并降解另一种死亡结构域受体Fas,并通过Fas和TNF受体阻止细胞凋亡。之前还表明,RID可促使表皮生长因子受体内化和降解。之前表明,E1B-19K可通过Fas阻断细胞凋亡,并且发现E1B-19K和E3-14.7K均可通过TNF受体阻止细胞凋亡。这些发现表明,TRAIL、Fas配体和TNF的受体在限制病毒感染中发挥作用。腺病毒通过这些受体抑制杀伤的能力可能会延长急性和持续性感染。